BIOVIE INC BIVI 深 滬
已收盤 07-25 16:00:00 美东时间
7.48
-0.070
-0.93%
華盛通- 最 高7.58
- 今 開7.54
- 成交量 2.42万股
- 最 低 7.32
- 昨 收 7.55
- 總市值 1389.11万
- 52周最高 75.00
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 6.20
- 委 比 -50.25%
- 總股本 185.71万
- 歷史最高 4609.80
- 量 比 0.40
- 振 幅 3.44%
- 歷史最低 6.20
- 每 手 1
- 風險率 9.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
BioVie Inc. presented research on Bezisterim, a drug candidate modulating inflammation and insulin sensitivity, at the World Conference on Aging and Gerentology (WCAG-2025). The study showed that Bezisterim significantly decelerated biological aging in Alzheimer’s Disease patients, reducing age acceleration by up to 4.24 years on certain clocks. It also decreased inflammatory cytokines like TNFα, IL-6, and IL-17, and improved metabolic biomarkers...
07-24 12:00
BioVie Expands Board Amid Drug Development Momentum
The latest update is out from BioVie ( ($BIVI) ). On July 17, 2025, BioVie Inc....
07-24 05:27
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
BioVie Inc. has appointed Amy S. Chappell, MD, and Kameel D. Farag to its Board of Directors, bringing significant expertise in neuroscience drug development and financial growth. Dr. Chappell, a seasoned neurologist with extensive experience in CNS drug approvals, joins from Solaxa Inc. Mr. Farag, a financial leader with a track record in scaling biotech companies, previously led Aspen Neuroscience. Their expertise will support BioVie’s Phase 2 ...
07-22 12:00
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
BioVie Inc. presented findings at the World Aging and Rejuvenation Conference (ARC-2025) in Vienna, highlighting the potential of its drug candidate, bezisterim, in addressing aging and neurodegeneration through anti-inflammatory epigenetic mechanisms. Data from the Phase 3 NM101 study indicated that bezisterim may slow biological aging by 3.16 to 4.24 years, based on five epigenetic clocks, and improved metabolic and inflammatory biomarkers in p...
07-09 12:00
BioVie Announces 1-for-10 Reverse Stock Split
BioVie ( ($BIVI) ) has issued an update. On June 23, 2025, BioVie Inc.’s stockh...
06-28 05:50
BioVie Approves Reverse Stock Split Authority
An update from BioVie ( ($BIVI) ) is now available. On June 23, 2025, BioVie In...
06-25 05:50
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
<p><p align="justify">BioVie Inc. (NASDAQ: BIVI) will present a poster on the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson’s disease at the Advanced Therapeutics in Movement & Related Disorders® Congress in National Harbor, MD, June 27-30, 2025. The trial features a hybrid decentralized design, allowing patients to participate either from their homes or at clinical s...
06-24 20:05
BioVie Enrolls First Patient In Phase 2 ADDRESS-LC Clinical Trial Evaluating Bezisterim For Treatment Of Neurological Symptoms Associated With Long COVID; Expects Topline Data To Be Available In H1 2026
Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fogEvidence suggests sustained inflammation
05-15 20:15
BioVie Announces It Will Present Rationale And Design of Phase 2 SUNRISE-PD Clinical Trial At 30th World Congress On Parkinson's Disease And Related Disorders May 7-10, 2025 In New York City
BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver
05-07 20:02
